Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements.

Based on the 2013 version, this update Report provides detailed analysis on Chinese government policies about dialysis industry and the relevant effect in recent three years, and conducts in-depth research about dialysis industry segmentations. Moreover, it analyzes Chinese private-owned hemodialysis services. In the aspect of enterprises, this update Report not only updates the latest information about the key enterprises listed in 2013 version, but also adds the information about some enterprises who intend to enter into this industry. This update Report reflects an overall development situation of China’s dialysis industry and provides references for investors and entrepreneurs.

In China, hemodialysis treatment has gained a wide popularity. By the end of 2013, the number of dialysis centers has amounted to 3637, contributing a make scale of CNY 14.4 billion, in which, hemodialysis was CNY 11.5 billion, and peritoneal dialysis was CNY 2.9 billion.

Foreign enterprises, such as, Germany Fresenius, Japan Nikkiso and Asahi Kasei, have dominated China’s dialysis market. Chinese enterprises mainly are engaged in the production of dialysis tubing or dialysate and other low technology content products. And few Chinese enterprises are specialized in manufacturing dialysis machines and dialyzers or other high end products. Now the situation improved a little, Chinese enterprise Weigao has led China’s hemodialysis machines and dialyzers manufacture, and Chinese enterprise Huaren Pharma has led China’s peritoneal dialysis industry.

By the end of May 2014, rural residence critical illness insurance program has already covered over 50% counties (cities and districts) in whole China. And in Shandong, Tianjin, Jilin, Gansu, and Qinghai, and some other cities and provinces, the critical illness insurance program is in full swing, and the provincial government has implemented the overall planning in each administrative region. Radiant Insights believes that along with the gradual implementation of critical illness program in China, more and more ESRD (End Stage Renal Disease) patients will enjoy the insurance guarantee. Therefore, China’s dialysis industry is entering into golden development stage.

3. Current Status of China’s Dialysis Market
3.1 Development Status
3.2 Competition Landscape of Product Segmentations
3.3 Policy Environment
3.3.1 Gradual Implementation of Critical Illness Insurance Program
3.3.2 Dialysis treatment has the priority to enjoy more benefits in the current short term, while the situation in the long run is determined by Medical Insurance Policy
3.3.3 Exposure Draft Regarding the Independence of the Management Regulations and Basic Standards of Hemodialysis Center issued by NHFPC (National Health and Family Planning Commission of China): with obvious intention to ease the industry access and the openness is appealing
3.3.4 Key Tasks for Deepening the Reform of Health System in 2014: actively promote social capital to invest in and set up medical institutions

About Radiant Insights:Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. It assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.